Avis aux professionnels de la santé concernant le risque d’interactions médicamenteuses entre Paxlovid et les anticoagulants
Les professionnels de la santé doivent savoir qu’il existe un risque d’interactions médicamenteuses entre les anticoagulants oraux directs (AOD) et un ingrédient de Paxlovid (le ritonavir) chez les patients traités Read More
Alert to Health Care Professionals about a potential drug-drug interaction between Paxlovid and anticoagulants
In patients who are receiving a direct oral anticoagulant (DOAC), especially apixaban and rivaroxaban, and may be eligible to receive the antiviral drug Paxlovid for the treatment of COVID-19, health Read More
Déclaration concernant le vaccin d’AstraZeneca contre la COVID-19
Déclaration concernant le vaccin d’AstraZeneca contre la COVID-19 Toronto, Ontario (26 avril 2021) Thrombose Canada tient compte de la recommandation du Comité consultatif national de l’immunisation (CCNI) que le vaccin Read More
AstraZeneca COVID-19 Vaccine Statement April 26
(Toronto, Ontario April 26, 2021) – Thrombosis Canada acknowledges the recommendation of the National Advisory Committee on Immunization (NACI) that the AstraZeneca SARS-CoV-2 vaccine may be offered to individuals 30 Read More
Déclaration française 18 mars
ÉNONCÉ MIS À JOUR DE THROMBOSE CANADA CONCERNANT LE VACCIN D’ASTRAZENECA ET LES CAILLOTS SANGUINS Thrombose Canada veut rassurer le public en ce qui concerne le risque de formation de Read More
TC Updated Statement March 18
THROMBOSIS CANADA UPDATED STATEMENT ON ASTRAZENECA VACCINE AND BLOOD CLOTS Thrombosis Canada seeks to reassure the public regarding blood clot risk and COVID-19 vaccines Toronto, Ontario (March 18, 2021) – Read More
Thrombosis Canada Guidance on COVID-19 Vaccines and Anticoagulation
As COVID-19 vaccine distribution and administration ramps up in Canada, physicians and patients are asking about managing vaccination in people who are receiving anticoagulant (blood thinning) therapy. This issue is Read More